- Home
- ABVC vs ATNM Comparison
ABVC vs ATNM Comparison
Compare ABVC & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ABVC | ATNM |
|---|---|---|
| Founded | 2015 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.9M | 36.8M |
| IPO Year | 2009 | 2013 |
Fundamental Metrics
Financial Performance| Metric | ABVC | ATNM |
|---|---|---|
| Price | $1.08 | $0.99 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $4.50 |
| AVG Volume (30 Days) | 48.5K | ★ 113.0K |
| Earning Date | 03-03-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 7.14 | ★ 14.17 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $509,589.00 | $90,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 11.11 |
| 52 Week Low | $0.74 | $0.95 |
| 52 Week High | $4.02 | $1.95 |
Technical Indicators
Market Signals| Indicator | ABVC | ATNM |
|---|---|---|
| Relative Strength Index (RSI) | 35.36 | 34.91 |
| Support Level | N/A | N/A |
| Resistance Level | $1.67 | $1.71 |
| Average True Range (ATR) | 0.12 | 0.06 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 29.19 | 17.35 |
Price Performance
Historical ComparisonAbout ABVC ABVC BioPharma Inc.
ABVC BioPharma Inc is a clinical stage biopharmaceutical company focused on development of new drugs and medical devices, all of which are derived from plants. It currently has six drugs and three medical devices in development. The firm specializes in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes. Its products include: Vitargus - ABV-1701, ABV-2001, ABV-2002, MDD ABV-1504, ADHD ABV-1505, ADHD ABV-1601, ABV-1501, ABV-1702, and ABV-1703.
About ATNM Actinium Pharmaceuticals Inc. (Delaware)
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.